2021
Characterization of Bone Marrow Progenitor Cell Uterine Engraftment and Transdifferentiation
Mamillapalli R, Mutlu L, Taylor HS. Characterization of Bone Marrow Progenitor Cell Uterine Engraftment and Transdifferentiation. Reproductive Sciences 2021, 29: 2382-2390. PMID: 34515983, DOI: 10.1007/s43032-021-00738-5.Peer-Reviewed Original ResearchConceptsBone marrow-derived stem cellsRecipient miceBone marrow-derived cellsProgenitor cellsBone marrow transplantMarrow-derived cellsMarrow-derived stem cellsSpecific uterine cell typesBone marrow-derived progenitorsMarrow-derived progenitorsUterine cell typesUpregulation of markersCell surface markersStem cellsSpecific stem cell markersStem cell markersCell typesUterine repairMarrow transplantStem cell componentUterine tissueMurine modelMaintenance of fertilityDifferentiation of BMSCsCell markersTet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes
Rui J, Deng S, Perdigoto AL, Ponath G, Kursawe R, Lawlor N, Sumida T, Levine-Ritterman M, Stitzel ML, Pitt D, Lu J, Herold KC. Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes. Nature Communications 2021, 12: 5074. PMID: 34417463, PMCID: PMC8379260, DOI: 10.1038/s41467-021-25367-z.Peer-Reviewed Original ResearchConceptsImmune cellsΒ-cellsNOD/SCID recipientsDiabetogenic immune cellsDiabetogenic T cellsBone marrow transplantType 1 diabetesExpression of TET2Human β-cellsIslet infiltratesSCID recipientsMarrow transplantInflammatory pathwaysTransfer of diseaseT cellsInflammatory genesImmune killingPathologic interactionsReduced expressionDiabetesInflammationTET2MiceRecipientsCellsEmerging follicular activation strategies to treat women with poor ovarian response and primary ovarian insufficiency
Reig A, Herraiz S, Pellicer A, Seli E. Emerging follicular activation strategies to treat women with poor ovarian response and primary ovarian insufficiency. Current Opinion In Obstetrics & Gynecology 2021, 33: 241-248. PMID: 33896920, DOI: 10.1097/gco.0000000000000703.Peer-Reviewed Original ResearchConceptsPoor ovarian responsePrimary ovarian insufficiencyLive birthsOngoing pregnancyOvarian responseOvarian insufficiencyAutologous platelet-rich plasmaBone marrow transplantFemale reproductive agingPlatelet-rich plasmaIntraovarian injectionOvarian transplantationMarrow transplantReproductive agingFertility treatmentReproductive medicineWomenPregnancyBirthInsufficiencyPrevious reportsPreliminary studyMechanical disruptionAkt stimulationCutting-edge strategies
2020
Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease
Bakshi N, Katoch D, Sinha C, Ross D, Quarmyne M, Loewenstein G, Krishnamurti L. Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease. JAMA Network Open 2020, 3: e206742. PMID: 32469414, PMCID: PMC7260617, DOI: 10.1001/jamanetworkopen.2020.6742.Peer-Reviewed Original ResearchConceptsBone marrow transplantCaregivers of patientsSickle cell diseasePatient decision aidMarrow transplantMedian ageCurative treatmentCell diseaseGroup 2Group 1Caregiver attitudesNovel disease-modifying therapiesDisease-modifying therapiesSickle cell clinicAssessment of patientsFuture prospective studiesRandomized clinical trialsParent trialProspective studyTreatment optionsClinical trialsNeeds assessment phaseMAIN OUTCOMECell clinicPatients
2019
Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis
Price NL, Miguel V, Ding W, Singh AK, Malik S, Rotllan N, Moshnikova A, Toczek J, Zeiss C, Sadeghi MM, Arias N, Baldán Á, Andreev OA, Rodríguez-Puyol D, Bahal R, Reshetnyak YK, Suárez Y, Fernández-Hernando C, Lamas S. Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis. JCI Insight 2019, 4 PMID: 31613798, PMCID: PMC6948871, DOI: 10.1172/jci.insight.131102.Peer-Reviewed Original ResearchConceptsFatty acid oxidationChronic kidney diseaseKidney diseaseDisease progressionMiR-33Bone marrow transplantExtent of fibrosisDevelopment of fibrosisAttractive therapeutic targetExpression of factorsNucleic acid inhibitorsMarrow transplantKidney fibrosisFibrotic kidneysMouse modelTherapeutic targetLipid metabolismPharmacological inhibitionFibrosisLipid accumulationDiseaseGenetic deficiencyProgressionKidneyAcid oxidation
2018
HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study
Nickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816. DOI: 10.1182/blood-2018-99-114116.Peer-Reviewed Original ResearchBone marrow transplantHLA class ISickle cell diseaseHLA-identical bone marrow transplantsMore platelet transfusionsNon-alloimmunized patientsPlatelet transfusion supportPlatelet transfusionsRBC transfusionClass IPositive PRAPre-BMTTransfusion supportPediatric patientsMarrow transplantCell diseaseBone marrowRed blood cell transfusionHepatic sinusoidal obstruction syndromeApheresis platelet transfusionHLA-disparate donorsBlood cell transfusionSinusoidal obstruction syndromePlatelet transfusion requirementsCord blood graftsOvarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell disease
Phillips L, Krishnamurti L, Rytting H, Olson T. Ovarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell disease. Pediatric Blood & Cancer 2018, 65: e27367. PMID: 30039911, DOI: 10.1002/pbc.27367.Peer-Reviewed Original Research
2017
Mycobacterium grossiae sp. nov., a rapidly growing, scotochromogenic species isolated from human clinical respiratory and blood culture specimens
Paniz-Mondolfi AE, Greninger AL, Ladutko L, Brown-Elliott BA, Vasireddy R, Jakubiec W, Vasireddy S, Wallace RJ, Simmon KE, Dunn BE, Jackoway G, Vora SB, Quinn KK, Qin X, Campbell S. Mycobacterium grossiae sp. nov., a rapidly growing, scotochromogenic species isolated from human clinical respiratory and blood culture specimens. International Journal Of Systematic And Evolutionary Microbiology 2017, 67: 4345-4351. PMID: 28984546, DOI: 10.1099/ijsem.0.002216.Peer-Reviewed Original ResearchConceptsSevere chronic obstructive pulmonary diseasePost-bone marrow transplantChronic obstructive pulmonary diseaseSusceptibility testingDoxycycline/minocyclineObstructive pulmonary diseaseBone marrow transplantMycobacterium avium complexBlood culture specimensLaboratory Standards InstituteAntimicrobial susceptibility testingScotochromogenic speciesTuberculosis exposurePulmonary diseaseMarrow transplantMycobacterium wolinskyiCulture specimensAvium complexIntermediate susceptibilityGas-liquid chromatography analysisClinical sourcesStandards InstituteIsolatesMycobacteriaBiochemical profilingMedical Therapies for Endometriosis Differentially Inhibit Stem Cell Recruitment
Sahin Ersoy GS, Zolbin MM, Cosar E, Mamillapalli R, Taylor HS. Medical Therapies for Endometriosis Differentially Inhibit Stem Cell Recruitment. Reproductive Sciences 2017, 24: 818-823. PMID: 28256937, DOI: 10.1177/1933719116682879.Peer-Reviewed Original ResearchConceptsBone marrow-derived stem cellsMedroxyprogesterone acetateEstrogen deprivationEndometriosis lesionsStem cell recruitmentCell recruitmentLesions of endometriosisGreen fluorescent protein miceWeeks of treatmentBone marrow transplantLong-term treatmentMarrow-derived stem cellsStem cellsProgestin medroxyprogesterone acetateLong-term regressionBone marrow stem cellsStem cell engraftmentMarrow stem cellsProgestin therapyEndometriosis treatmentLesion regressionMedical therapyEndometriotic lesionsMarrow transplantC57BL/6 mice
2016
Discovery of the First Pathogenic Human EPO Mutation Provides Mechanistic Insight into Cytokine Signaling
Kim A, Ulirsch J, Wilmes S, Unal E, Moraga I, Karakukcu M, Yuan D, Kazerounian S, Gupta N, Gabriel S, Lander E, Patiroglu T, Ozcan A, Ozdemir M, Garcia C, Piehler J, Gazda H, Klein D, Sankaran V. Discovery of the First Pathogenic Human EPO Mutation Provides Mechanistic Insight into Cytokine Signaling. Blood 2016, 128: 331. DOI: 10.1182/blood.v128.22.331.331.Peer-Reviewed Original ResearchDiamond-Blackfan anemiaWhole-exome sequencing dataEPO receptorPotent concentrationAllogeneic bone marrow transplantBone marrow transplantBone marrow failure disordersYears of ageIntracellular flow cytometryMarrow failure disordersSerum EPO levelsExome sequencing dataMajority of casesAnemia correctionHost diseaseSevere graftDonor chimerismRed blood cellsMarrow transplantResultant complicationsLow doseRare caseSide effectsPatientsBone marrowDelayed bilateral fibrinous anterior chamber reaction following autologous bone marrow transplant and cataract surgery
Kavoussi SC, Kovacs KD, Alasil T, Coady P, Kombo N. Delayed bilateral fibrinous anterior chamber reaction following autologous bone marrow transplant and cataract surgery. American Journal Of Ophthalmology Case Reports 2016, 2: 8-10. PMID: 29503889, PMCID: PMC5757366, DOI: 10.1016/j.ajoc.2016.04.005.Peer-Reviewed Original ResearchImmune reconstitution uveitisBlood cell count recoveryAutologous bone marrow transplantCell count recoveryBone marrow transplantInfectious etiologyCount recoveryMarrow transplantFibrinous anterior chamber reactionWhite blood cell countActive antiretroviral therapyAnterior chamber cellsAnterior chamber reactionIntraocular lens placementBlood cell countLatent cytomegalovirusPatient's inflammationRebound inflammationAntiretroviral therapyIatrogenic immunosuppressionTopical steroidsClinical presentationTransient immunosuppressionCataract surgeryLens placement
2015
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. Journal For ImmunoTherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.Peer-Reviewed Original ResearchAllogeneic stem cell transplantationStem cell transplantationMetastatic melanomaCell transplantationAllogeneic bone marrow transplantSafety of immunotherapyPost-transplant patientsBone marrow transplantHost diseaseTransplant patientsImmune therapyMarrow transplantTheoretical riskMelanomaImmunotherapyPatientsTransplantationTherapyGVHDTransplantGraftDisease
2012
Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease
Hanash A, Dudakov J, Hua G, O’Connor M, Young L, Singer N, West M, Jenq R, Holland A, Kappel L, Ghosh A, Tsai J, Rao U, Yim N, Smith O, Velardi E, Hawryluk E, Murphy G, Liu C, Fouser L, Kolesnick R, Blazar B, van den Brink M. Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease. Immunity 2012, 37: 339-350. PMID: 22921121, PMCID: PMC3477611, DOI: 10.1016/j.immuni.2012.05.028.Peer-Reviewed Original ResearchConceptsIL-23-responsive innate lymphoid cellsIntestinal IL-22IL-22Intestinal stem cellsTissue damageHost diseaseTransplant recipientsIL-22 deficiencyInflammatory intestinal damageDonor immune systemInnate lymphoid cellsBone marrow transplantIL-22 receptorStem cellsILC frequenciesPretransplant conditioningIntestinal damageMarrow transplantCrypt apoptosisLymphoid cellsImmune systemGVHDTissue sensitivityProtective factorsEpithelial integrityLBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice
Wang D, Iclozan C, Liu C, Xia C, Anasetti C, Yu X. LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice. Transplantation And Cellular Therapy 2012, 18: 1182-1190.e1. PMID: 22698484, PMCID: PMC3417119, DOI: 10.1016/j.bbmt.2012.06.002.Peer-Reviewed Original ResearchConceptsBone marrow transplantSuberoylanilide hydroxamic acidAllogeneic bone marrow transplantAllogeneic transplant modelElevated Th1 cytokinesPrevention of GVHDDonor T cellsT cell infiltrationHistone deacetylase inhibitorsT cell activationTumor cell growthCXCR3 expressionHost diseaseRecipient serumPan-HDACiTh1 cytokinesMarrow transplantProinflammatory cytokinesTransplant modelCell infiltrationInflammatory diseasesGVHDT cellsMouse modelDisease amelioration
2010
Stem cells and reproduction
Du H, Taylor HS. Stem cells and reproduction. Current Opinion In Obstetrics & Gynecology 2010, 22: 235-241. PMID: 20305558, PMCID: PMC3107846, DOI: 10.1097/gco.0b013e328338c152.Peer-Reviewed Original ResearchConceptsStem cellsCause of endometriosisBone marrow transplantBone marrow stem cellsMarrow stem cellsStem cell biologyEndometrial regenerationMarrow transplantUterine disordersFetal stem cellsOrthotopic transplantationOvarian cancerMaternal circulationLive birthsEnd organsOvarian tissueFetal cellsUnderlying causeClinical potentialCell biologyMature oocytesDynamic organCell transformationNovel evidenceWomen
2008
Recipient Langerhans Cells Are Neither Required Nor Sufficient for GVHD Induction in MHC-Matched Allogeneic BMT, but a Langerin+ Cell Is a Pivotal Regulator of Langerhans Cell Turnover Post Transplantation
Li H, Kaplan D, Demetris A, McNiff J, Shlomchik M, Shlomchik W. Recipient Langerhans Cells Are Neither Required Nor Sufficient for GVHD Induction in MHC-Matched Allogeneic BMT, but a Langerin+ Cell Is a Pivotal Regulator of Langerhans Cell Turnover Post Transplantation. Blood 2008, 112: 3511. DOI: 10.1182/blood.v112.11.3511.3511.Peer-Reviewed Original ResearchRecipient antigen-presenting cellsHost Langerhans cellsAntigen-presenting cellsBone marrow transplantAllogeneic bone marrow transplantRecipient Langerhans cellsDonor T cellsGVHD inductionEpidermal Langerhans cellsLangerhans cellsBone marrowSkin GVHDMarrow transplantT cellsAllogeneic donor T cellsAlloreactive donor T cellsDonor-derived Langerhans cellsMajor antigen-presenting cellsHost antigen-presenting cellsProfessional antigen-presenting cellsWeight lossDonor Langerhans cellsExpression of langerinTime of transplantUV-induced inflammationIL-17 contributes to CD4-mediated graft-versus-host disease
Kappel L, Goldberg G, King C, Suh D, Smith O, Ligh C, Holland A, Grubin J, Mark N, Liu C, Iwakura Y, Heller G, van den Brink M. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2008, 113: 945-952. PMID: 18931341, PMCID: PMC2630280, DOI: 10.1182/blood-2008-08-172155.Peer-Reviewed Original ResearchConceptsRecipients of ILT cellsGVHD mortalityHost diseaseIL-17Proinflammatory cytokinesAllogeneic bone marrow transplantAllogeneic BMT modelIL-17 contributesDonor T cellsBone marrow transplantWhole T cellsT-cell recipientsAcute graftGVHD developmentGVT activityAllograft rejectionTh17 cellsIL-17FIL-22Interleukin-17Marrow transplantAutoimmune diseasesTh1 cellsLymphoid organs
2007
A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses
Duran-Struuck R, Tawara I, Lowler K, Clouthier S, Weisiger E, Rogers C, Luker G, Kumanogoh A, Liu C, Ferrara J, Reddy P. A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses. Transplantation And Cellular Therapy 2007, 13: 1294.e1-1294.e11. PMID: 17950916, PMCID: PMC2278022, DOI: 10.1016/j.bbmt.2007.07.014.Peer-Reviewed Original ResearchConceptsBone marrow transplantT cellsWT T cellsDendritic cellsBALB/c recipient miceIntrinsic T cell defectPreservation of GVLAllo-immune responsesLess TNF-alphaTumor-free survivalT cell defectsAntigen presenting cellsWild-type T cellsCertain immune responsesP815 murine mastocytoma cell lineT cell-APC interactionsFree survivalHost diseaseIL-12p70Leukemia responseOrgan damageSema4D expressionMarrow transplantCytotoxic functionSyngeneic recipients
2003
Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 170-176. DOI: 10.1016/s1083-8791(03)70006-8.Peer-Reviewed Original ResearchConceptsReduced-intensity preparative regimenHost dendritic cellsReduced-intensity regimenPreparative regimenTotal body irradiationDendritic cellsAcute GVHDChronic GVHDDC chimerismConventional regimenBody irradiationAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAllogeneic stem cell transplantationExtensive chronic GVHDDevelopment of GVHDStem cell transplantationBone marrow transplantationBone marrow transplantExtracorporeal photophoresisHost diseaseMarrow transplantationSignificant morbidityMarrow transplantCell transplantation
2002
Radiation pneumonitis in mice A severe injury model for pneumocyte engraftment from bone marrow
Theise ND, Henegariu O, Grove J, Jagirdar J, Kao PN, Crawford JM, Badve S, Saxena R, Krause DS. Radiation pneumonitis in mice A severe injury model for pneumocyte engraftment from bone marrow. Experimental Hematology 2002, 30: 1333-1338. PMID: 12423687, DOI: 10.1016/s0301-472x(02)00931-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersBone Marrow TransplantationCell DifferentiationCell LineageEpithelial CellsFemaleGraft SurvivalIn Situ Hybridization, FluorescenceLungMaleMiceModels, AnimalPulmonary AlveoliPulmonary Surfactant-Associated Protein BRadiation ChimeraRadiation PneumonitisRNA, MessengerStem Cell TransplantationStem CellsY ChromosomeConceptsBone marrow transplantType II pneumocytesBone marrow cellsFemale miceLethal irradiationAge-matched male donorsWhole bone marrow transplantsMarrow cellsDay 5 posttransplantAlveolar lining cellsFluorescence-activated cell sorterSevere injury modelType I cellsAlveolar breakdownEntire alveoliRadiation pneumonitisB messenger RNAHistologic evidenceMarrow transplantAcute injuryMonth 2Injury modelLung tissueLining cellsBone marrow
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply